China
Country
Henlius is advancing its nivolumab biosimilar HLX18 into Chinese trials, as it expands a global oncology pipeline. In 2025, the firm’s strong revenue growth was offset by rising R&D investment amid increasing contributions from overseas partnerships.
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
US Trade Representative is taking two swings under Section 301(b) of the 1974 Trade Act. Customs and Border Protection has March 19 to provide US Court of International Trade with next update on its progress on providing refunds for IEEPA tariffs.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talk to the Pink Sheet about clinical trials amid global turmoil, the slowdown in big pharma decision-making and pivot in some cases to the FSP outsourcing model, evolving DCT definitions and India opportunities.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.